AnaptysBio Key Executives
This section highlights AnaptysBio's key executives, including their titles and compensation details.
Find Contacts at AnaptysBio
(Showing 0 of )
AnaptysBio Earnings
This section highlights AnaptysBio's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
$18.59
Stock Price
$570.10M
Market Cap
136
Employees
San Diego, CA
Location
Financial Statements
Access annual & quarterly financial statements for AnaptysBio, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $91.28M | $17.16M | $10.29M | $63.17M | $75.00M |
| Cost of Revenue | $- | $2.38M | $2.33M | $98.50M | $80.03M |
| Gross Profit | $91.28M | $14.78M | $7.95M | $-35.32M | $-5.03M |
| Gross Profit Ratio | 100.00% | 86.20% | 77.30% | -55.90% | -6.70% |
| Research and Development Expenses | $163.84M | $132.28M | $88.80M | $98.50M | $80.03M |
| General and Administrative Expenses | $42.39M | $41.95M | $36.64M | $21.49M | $18.85M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $42.39M | $41.95M | $36.64M | $21.49M | $18.85M |
| Other Expenses | $- | $7.34M | $12.00K | $37.00K | $-11.00K |
| Operating Expenses | $206.23M | $181.57M | $125.44M | $119.99M | $98.88M |
| Cost and Expenses | $206.23M | $181.57M | $125.44M | $119.99M | $98.88M |
| Interest Income | $19.79M | $18.87M | $7.55M | $431.00K | $3.96M |
| Interest Expense | $50.09M | $18.08M | $21.11M | $1.45M | $- |
| Depreciation and Amortization | $2.40M | $2.38M | $2.33M | $2.09M | $559.00K |
| EBITDA | $-92.74M | $-143.16M | $-105.26M | $-55.71M | $-19.37M |
| EBITDA Ratio | -101.60% | -834.43% | -1045.90% | -89.19% | -25.83% |
| Operating Income | $-114.95M | $-164.41M | $-115.15M | $-56.81M | $-23.88M |
| Operating Income Ratio | -125.93% | -958.27% | -1119.41% | -89.93% | -31.84% |
| Total Other Income Expenses Net | $-30.28M | $788.00K | $-13.55M | $-982.00K | $3.95M |
| Income Before Tax | $-145.23M | $-163.62M | $-128.70M | $-57.80M | $-19.93M |
| Income Before Tax Ratio | -159.10% | -953.68% | -1251.09% | -91.49% | -26.57% |
| Income Tax Expense | $3.00K | $-4.00K | $24.00K | $-603.00K | $-11.00K |
| Net Income | $-145.23M | $-163.62M | $-128.72M | $-57.19M | $-19.92M |
| Net Income Ratio | -159.10% | -953.66% | -1251.33% | -90.53% | -26.56% |
| EPS | $-5.12 | $-6.08 | $-4.57 | $-2.08 | $-0.73 |
| EPS Diluted | $-5.12 | $-6.08 | $-4.57 | $-2.08 | $-0.73 |
| Weighted Average Shares Outstanding | 28.38M | 26.92M | 28.16M | 27.43M | 27.30M |
| Weighted Average Shares Outstanding Diluted | 28.38M | 26.92M | 28.16M | 27.43M | 27.30M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $43.11M | $30.02M | $10.97M | $7.18M | $9.01M | $3.32M | $3.46M | $1.37M | $6.81M | $1.29M | $1.22M | $970.00K | $1.01M | $20.89M | $30.03M | $11.25M | $60.00M | $- | $- | $15.00M |
| Cost of Revenue | $- | $596.00K | $595.00K | $605.00K | $604.00K | $592.00K | $587.00K | $593.00K | $606.00K | $585.00K | $571.00K | $573.00K | $26.78M | $22.22M | $25.31M | $24.18M | $21.57M | $19.54M | $17.95M | $20.97M |
| Gross Profit | $43.11M | $29.42M | $10.38M | $6.57M | $8.40M | $2.73M | $2.87M | $781.00K | $6.20M | $708.00K | $645.00K | $397.00K | $-25.77M | $-1.33M | $4.71M | $-12.94M | $38.43M | $-19.54M | $-17.95M | $-5.97M |
| Gross Profit Ratio | 100.00% | 98.00% | 94.60% | 91.60% | 93.30% | 82.20% | 83.00% | 56.80% | 91.10% | 54.80% | 53.00% | 40.90% | -2548.50% | -6.40% | 15.70% | -115.00% | 64.05% | 0.00% | 0.00% | -39.79% |
| Research and Development Expenses | $42.59M | $42.21M | $41.84M | $36.88M | $33.52M | $30.88M | $32.92M | $34.96M | $23.37M | $22.06M | $20.84M | $22.52M | $26.78M | $22.22M | $25.31M | $24.18M | $21.57M | $19.54M | $17.95M | $20.97M |
| General and Administrative Expenses | $10.19M | $10.56M | $9.29M | $12.34M | $10.28M | $10.17M | $10.68M | $10.82M | $9.41M | $8.86M | $8.17M | $10.20M | $5.39M | $5.43M | $5.25M | $5.42M | $5.09M | $4.79M | $4.69M | $4.29M |
| Selling and Marketing Expenses | $- | $- | $-441.00K | $-442.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $10.19M | $10.56M | $8.85M | $11.90M | $10.28M | $10.17M | $10.68M | $10.82M | $9.41M | $8.86M | $8.17M | $10.20M | $5.39M | $5.43M | $5.25M | $5.42M | $5.09M | $4.79M | $4.69M | $4.29M |
| Other Expenses | $- | $- | $- | $-2.00K | $7.34M | $1.00K | $3.00K | $-4.00K | $-4.00K | $4.00K | $6.00K | $6.00K | $1.00K | $33.00K | $- | $3.00K | $-75.00K | $-56.00K | $26.00K | $94.00K |
| Operating Expenses | $52.78M | $52.77M | $50.70M | $48.77M | $43.80M | $41.05M | $43.60M | $45.77M | $32.78M | $30.93M | $29.02M | $32.72M | $32.17M | $27.65M | $30.56M | $29.61M | $26.66M | $24.34M | $22.64M | $25.25M |
| Cost and Expenses | $52.78M | $52.77M | $51.29M | $49.38M | $43.80M | $41.05M | $43.60M | $45.77M | $32.78M | $30.93M | $29.02M | $32.72M | $32.17M | $27.65M | $30.56M | $29.61M | $26.66M | $24.34M | $22.64M | $25.25M |
| Interest Income | $5.26M | $5.32M | $4.62M | $4.58M | $4.88M | $4.85M | $4.65M | $4.49M | $3.84M | $2.26M | $1.11M | $342.00K | $68.00K | $64.00K | $104.00K | $195.00K | $376.00K | $625.00K | $1.06M | $1.90M |
| Interest Expense | $17.40M | $15.41M | $10.95M | $6.32M | $4.96M | $4.43M | $4.36M | $4.34M | $4.25M | $6.13M | $5.87M | $4.85M | $1.45M | $- | $- | $- | $- | $- | $- | $- |
| Depreciation and Amortization | $601.00K | $596.00K | $595.00K | $605.00K | $604.00K | $592.00K | $587.00K | $593.00K | $606.00K | $585.00K | $571.00K | $573.00K | $385.00K | $669.00K | $911.00K | $125.00K | $144.00K | $138.00K | $137.00K | $140.00K |
| EBITDA | $-3.79M | $-16.84M | $-35.10M | $-37.01M | $-36.65M | $-32.28M | $-34.90M | $-39.33M | $-21.53M | $-26.78M | $-26.11M | $-30.83M | $-30.99M | $-6.00M | $356.00K | $-18.04M | $33.79M | $-24.20M | $-22.50M | $-10.11M |
| EBITDA Ratio | -8.78% | -56.11% | -362.10% | -579.41% | -407.03% | -973.03% | -1008.67% | -2905.31% | -325.18% | -2071.31% | -2147.62% | -3178.14% | -3074.98% | -29.17% | 1.26% | -162.14% | 56.32% | 0.00% | 0.00% | -54.15% |
| Operating Income | $-9.67M | $-22.76M | $-40.32M | $-42.20M | $-42.13M | $-37.73M | $-40.14M | $-44.40M | $-25.97M | $-29.63M | $-27.80M | $-31.75M | $-31.16M | $-6.76M | $-533.00K | $-18.36M | $33.34M | $-24.34M | $-22.64M | $-10.25M |
| Operating Income Ratio | -22.43% | -75.81% | -367.52% | -587.84% | -467.91% | -1137.19% | -1160.20% | -3231.51% | -381.51% | -2291.80% | -2286.10% | -3273.09% | -3081.80% | -32.37% | -1.78% | -163.25% | 55.57% | 0.00% | 0.00% | -68.35% |
| Total Other Income Expenses Net | $-12.12M | $-10.09M | $-6.33M | $-1.74M | $-80.00K | $424.00K | $298.00K | $146.00K | $-416.00K | $-3.87M | $-4.75M | $-4.51M | $-1.38M | $97.00K | $104.00K | $198.00K | $301.00K | $569.00K | $1.09M | $1.99M |
| Income Before Tax | $-21.79M | $-32.85M | $-46.65M | $-43.94M | $-42.22M | $-37.31M | $-39.84M | $-44.26M | $-26.39M | $-33.50M | $-32.55M | $-36.26M | $-32.54M | $-6.67M | $-429.00K | $-18.16M | $33.65M | $-23.77M | $-21.55M | $-8.26M |
| Income Before Tax Ratio | -50.54% | -109.44% | -425.22% | -612.01% | -468.80% | -1124.41% | -1151.59% | -3220.89% | -387.62% | -2591.03% | -2677.14% | -3737.63% | -3218.40% | -31.91% | -1.43% | -161.49% | 56.08% | 0.00% | 0.00% | -55.08% |
| Income Tax Expense | $-6.00K | $- | $9.00K | $561.72K | $4.87M | $4.43M | $4.36M | $4.19M | $24.00K | $3.87M | $4.75M | $4.51M | $-1.45M | $-64.00K | $- | $-195.00K | $-75.00K | $-56.00K | $26.00K | $94.00K |
| Net Income | $-21.78M | $-32.85M | $-46.66M | $-43.94M | $-42.21M | $-37.31M | $-39.84M | $-48.45M | $-26.41M | $-37.37M | $-37.31M | $-40.76M | $-32.54M | $-6.67M | $-429.00K | $-18.16M | $33.65M | $-23.77M | $-21.55M | $-8.26M |
| Net Income Ratio | -50.53% | -109.44% | -425.30% | -612.01% | -468.75% | -1124.41% | -1151.59% | -3525.84% | -387.97% | -2890.26% | -3068.17% | -4202.16% | -3218.40% | -31.91% | -1.43% | -161.49% | 56.08% | 0.00% | 0.00% | -55.08% |
| EPS | $-0.77 | $-1.14 | $-1.71 | $-1.64 | $-1.59 | $-1.41 | $-1.50 | $-1.73 | $-0.93 | $-1.32 | $-1.32 | $-1.47 | $-1.18 | $-0.24 | $-0.02 | $-0.66 | $1.23 | $-0.87 | $-0.79 | $-0.30 |
| EPS Diluted | $-0.77 | $-1.14 | $-1.71 | $-1.64 | $-1.59 | $-1.41 | $-1.50 | $-1.73 | $-0.93 | $-1.32 | $-1.32 | $-1.47 | $-1.18 | $-0.24 | $-0.02 | $-0.66 | $1.23 | $-0.87 | $-0.79 | $-0.30 |
| Weighted Average Shares Outstanding | 28.38M | 28.89M | 27.36M | 26.80M | 26.59M | 26.55M | 26.63M | 27.95M | 28.45M | 28.29M | 28.20M | 27.71M | 27.53M | 27.44M | 27.39M | 27.36M | 27.35M | 27.32M | 27.28M | 27.26M |
| Weighted Average Shares Outstanding Diluted | 28.38M | 28.89M | 27.36M | 26.80M | 26.59M | 26.55M | 26.63M | 27.95M | 28.45M | 28.29M | 28.20M | 27.71M | 27.53M | 27.44M | 27.39M | 27.36M | 27.36M | 27.32M | 27.28M | 27.26M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $123.08M | $35.97M | $71.31M | $495.73M | $250.46M |
| Short Term Investments | $262.29M | $354.94M | $369.93M | $52.37M | $143.20M |
| Cash and Short Term Investments | $385.37M | $390.90M | $441.24M | $548.10M | $393.65M |
| Net Receivables | $40.77M | $6.85M | $1.42M | $876.00K | $- |
| Inventory | $- | $- | $1 | $1 | $- |
| Other Current Assets | $5.74M | $9.08M | $4.54M | $4.90M | $5.82M |
| Total Current Assets | $431.88M | $406.83M | $447.20M | $553.88M | $396.56M |
| Property Plant Equipment Net | $16.23M | $18.27M | $19.99M | $21.84M | $1.78M |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- |
| Long Term Investments | $35.47M | $27.03M | $142.94M | $67.10M | $17.55M |
| Tax Assets | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $256.00K | $256.00K | $256.00K | $256.00K | $662.00K |
| Total Non-Current Assets | $51.96M | $45.55M | $163.18M | $89.19M | $19.99M |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $483.83M | $452.39M | $610.38M | $643.07M | $416.55M |
| Account Payables | $4.00M | $4.70M | $2.78M | $1.74M | $4.22M |
| Short Term Debt | $1.93M | $1.78M | $3.27M | $3.01M | $342.00K |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $- | $- |
| Other Current Liabilities | $39.50M | $30.97M | $20.00M | $11.35M | $15.26M |
| Total Current Liabilities | $45.43M | $37.44M | $26.05M | $16.10M | $19.82M |
| Long Term Debt | $14.11M | $16.04M | $17.81M | $19.45M | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $353.43M | $310.81M | $304.41M | $251.09M | $- |
| Total Non-Current Liabilities | $367.54M | $326.84M | $322.23M | $270.54M | $- |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $412.97M | $364.29M | $348.28M | $286.64M | $19.82M |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $30.00K | $27.00K | $29.00K | $28.00K | $27.00K |
| Retained Earnings | $-759.33M | $-614.10M | $-450.48M | $-321.75M | $-263.96M |
| Accumulated Other Comprehensive Income Loss | $305.00K | $-797.00K | $-5.25M | $-422.00K | $-4.00K |
| Other Total Stockholders Equity | $829.86M | $702.97M | $717.80M | $678.58M | $660.66M |
| Total Stockholders Equity | $70.87M | $88.10M | $262.10M | $356.43M | $396.73M |
| Total Equity | $70.87M | $88.10M | $262.10M | $356.43M | $396.73M |
| Total Liabilities and Stockholders Equity | $483.83M | $452.39M | $610.38M | $643.07M | $416.55M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $483.83M | $452.39M | $610.38M | $643.07M | $416.55M |
| Total Investments | $297.76M | $381.96M | $512.87M | $119.47M | $160.74M |
| Total Debt | $16.04M | $17.81M | $19.45M | $20.95M | $342.00K |
| Net Debt | $-107.04M | $-18.15M | $-51.86M | $-474.77M | $-250.11M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $123.08M | $191.58M | $71.82M | $53.70M | $35.97M | $26.30M | $35.21M | $94.56M | $71.31M | $58.55M | $71.70M | $166.41M | $495.73M | $336.33M | $332.25M | $284.15M | $250.46M | $209.15M | $221.17M | $165.32M |
| Short Term Investments | $262.29M | $238.54M | $278.98M | $300.97M | $354.94M | $386.75M | $394.28M | $336.59M | $369.93M | $384.42M | $370.45M | $339.21M | $52.37M | $37.74M | $58.60M | $96.21M | $143.20M | $129.19M | $156.71M | $197.17M |
| Cash and Short Term Investments | $385.37M | $430.12M | $350.80M | $354.67M | $390.90M | $413.05M | $429.49M | $431.15M | $441.24M | $442.97M | $442.15M | $505.62M | $548.10M | $374.06M | $390.85M | $380.36M | $393.65M | $338.35M | $377.88M | $362.48M |
| Net Receivables | $40.77M | $12.20M | $9.01M | $7.09M | $6.85M | $3.27M | $3.18M | $1.52M | $1.42M | $1.18M | $- | $921.00K | $876.00K | $761.00K | $642.00K | $1.25M | $- | $- | $- | $5.00M |
| Inventory | $- | $- | $1 | $1 | $1 | $1 | $- | $1 | $1 | $- | $1 | $- | $-876.00K | $60.00K | $60.00K | $60.00K | $- | $- | $- | $- |
| Other Current Assets | $5.74M | $6.37M | $7.54M | $10.67M | $9.08M | $11.68M | $5.87M | $4.48M | $4.54M | $12.60M | $19.25M | $5.87M | $4.90M | $11.82M | $6.57M | $5.52M | $5.82M | $14.94M | $13.28M | $7.14M |
| Total Current Assets | $431.88M | $448.68M | $367.35M | $372.42M | $406.83M | $428.00M | $438.54M | $437.15M | $447.20M | $450.44M | $452.81M | $512.41M | $553.88M | $386.64M | $398.06M | $387.13M | $396.56M | $345.81M | $384.52M | $371.06M |
| Property Plant Equipment Net | $16.23M | $16.57M | $17.12M | $17.69M | $18.27M | $18.87M | $19.07M | $19.45M | $19.99M | $20.29M | $20.80M | $21.31M | $21.84M | $22.19M | $22.77M | $1.75M | $1.78M | $1.58M | $1.50M | $1.61M |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Long Term Investments | $35.47M | $27.91M | $42.65M | $15.47M | $27.03M | $40.20M | $59.24M | $94.93M | $142.94M | $147.51M | $129.99M | $91.19M | $67.10M | $15.24M | $5.48M | $7.06M | $17.55M | $36.18M | $14.32M | $50.22M |
| Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $256.00K | $256.00K | $256.00K | $256.00K | $256.00K | $256.00K | $256.00K | $256.00K | $256.00K | $256.00K | $256.00K | $256.00K | $256.00K | $258.00K | $258.00K | $477.00K | $662.00K | $1.17M | $1.41M | $1.35M |
| Total Non-Current Assets | $51.96M | $44.74M | $60.03M | $33.41M | $45.55M | $59.33M | $78.56M | $114.64M | $163.18M | $168.06M | $151.04M | $112.76M | $89.19M | $37.69M | $28.51M | $9.29M | $19.99M | $38.94M | $17.23M | $53.18M |
| Other Assets | $- | $- | $1 | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $483.83M | $493.42M | $427.38M | $405.83M | $452.39M | $487.33M | $517.10M | $551.79M | $610.38M | $618.50M | $603.85M | $625.17M | $643.07M | $424.33M | $426.57M | $396.42M | $416.55M | $384.75M | $401.75M | $424.23M |
| Account Payables | $4.00M | $3.59M | $4.89M | $4.58M | $4.70M | $6.52M | $4.76M | $3.17M | $2.78M | $3.01M | $1.59M | $2.48M | $1.74M | $5.72M | $4.10M | $2.45M | $4.22M | $5.48M | $6.29M | $8.57M |
| Short Term Debt | $1.93M | $3.77M | $3.70M | $1.81M | $3.55M | $3.48M | $3.41M | $3.34M | $3.27M | $3.21M | $3.14M | $3.07M | $3.01M | $2.19M | $1.11M | $197.00K | $342.00K | $851.00K | $925.00K | $898.00K |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $1.50M | $- | $- | $- | $- | $17.29M | $11.99M | $12.88M |
| Other Current Liabilities | $39.50M | $36.51M | $31.83M | $25.90M | $29.19M | $29.18M | $33.46M | $29.29M | $20.00M | $14.85M | $15.14M | $14.23M | $11.35M | $12.98M | $15.40M | $11.83M | $15.26M | $18.14M | $12.92M | $13.78M |
| Total Current Liabilities | $45.43M | $43.88M | $40.42M | $32.30M | $37.44M | $39.18M | $41.63M | $35.80M | $26.05M | $21.06M | $19.87M | $19.78M | $16.10M | $20.89M | $20.62M | $14.47M | $19.82M | $24.47M | $20.13M | $23.25M |
| Long Term Debt | $14.11M | $14.61M | $15.10M | $325.76M | $16.04M | $16.49M | $16.95M | $17.39M | $17.81M | $18.23M | $18.65M | $19.06M | $19.45M | $39.68M | $40.44M | $- | $- | $33.00K | $- | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $353.43M | $350.56M | $361.98M | $- | $310.81M | $311.27M | $310.07M | $307.52M | $304.41M | $301.59M | $261.02M | $255.58M | $251.09M | $-19.84M | $-20.22M | $- | $- | $- | $- | $- |
| Total Non-Current Liabilities | $367.54M | $365.17M | $377.08M | $325.76M | $326.84M | $327.76M | $327.02M | $324.90M | $322.23M | $319.82M | $279.67M | $274.64M | $270.54M | $19.84M | $20.22M | $- | $- | $33.00K | $180.00K | $419.00K |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $412.97M | $409.05M | $417.50M | $358.06M | $364.29M | $366.94M | $368.65M | $360.70M | $348.28M | $340.88M | $299.54M | $294.42M | $286.64M | $40.73M | $40.84M | $14.47M | $19.82M | $24.51M | $20.31M | $23.67M |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock | $30.00K | $30.00K | $27.00K | $27.00K | $27.00K | $27.00K | $27.00K | $27.00K | $29.00K | $28.00K | $28.00K | $28.00K | $28.00K | $27.00K | $27.00K | $27.00K | $27.00K | $27.00K | $27.00K | $27.00K |
| Retained Earnings | $-759.33M | $-737.54M | $-704.69M | $-658.03M | $-614.10M | $-571.88M | $-534.58M | $-494.73M | $-450.48M | $-424.06M | $-390.56M | $-358.01M | $-321.75M | $-289.21M | $-282.55M | $-282.12M | $-263.96M | $-297.60M | $-273.84M | $-252.29M |
| Accumulated Other Comprehensive Income Loss | $305.00K | $759.00K | $-415.00K | $-624.00K | $-797.00K | $-2.35M | $-3.61M | $-3.27M | $-5.25M | $-6.01M | $-3.86M | $-2.43M | $-422.00K | $-200.00K | $-176.00K | $-111.00K | $-4.00K | $259.00K | $753.00K | $1.15M |
| Other Total Stockholders Equity | $829.86M | $821.12M | $714.96M | $706.41M | $702.97M | $694.59M | $686.61M | $689.07M | $717.80M | $707.66M | $698.70M | $691.16M | $678.58M | $673.00M | $668.43M | $664.15M | $660.66M | $657.56M | $654.49M | $651.68M |
| Total Stockholders Equity | $70.87M | $84.37M | $9.88M | $47.78M | $88.10M | $120.38M | $148.45M | $191.09M | $262.10M | $277.62M | $304.31M | $330.75M | $356.43M | $383.61M | $385.73M | $381.94M | $396.73M | $360.24M | $381.44M | $400.56M |
| Total Equity | $70.87M | $84.37M | $9.88M | $47.78M | $88.10M | $120.38M | $148.45M | $191.09M | $262.10M | $277.62M | $304.31M | $330.75M | $356.43M | $383.61M | $385.73M | $381.94M | $396.73M | $360.24M | $381.44M | $400.56M |
| Total Liabilities and Stockholders Equity | $483.83M | $493.42M | $427.38M | $405.83M | $452.39M | $487.33M | $517.10M | $551.79M | $610.38M | $618.50M | $603.85M | $625.17M | $643.07M | $424.33M | $426.57M | $396.42M | $416.55M | $384.75M | $401.75M | $424.23M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $483.83M | $493.42M | $427.38M | $405.83M | $452.39M | $487.33M | $517.10M | $551.79M | $610.38M | $618.50M | $603.85M | $625.17M | $643.07M | $424.33M | $426.57M | $396.42M | $416.55M | $384.75M | $401.75M | $424.23M |
| Total Investments | $297.76M | $266.45M | $321.63M | $316.44M | $381.96M | $426.95M | $453.52M | $431.52M | $512.87M | $531.93M | $500.44M | $430.40M | $119.47M | $52.98M | $64.08M | $103.27M | $160.74M | $165.37M | $171.03M | $247.38M |
| Total Debt | $16.04M | $16.49M | $378.93M | $327.57M | $17.81M | $18.23M | $18.65M | $19.06M | $19.45M | $19.84M | $20.22M | $20.60M | $20.95M | $20.93M | $20.78M | $197.00K | $342.00K | $884.00K | $925.00K | $898.00K |
| Net Debt | $-107.04M | $-175.09M | $307.11M | $273.88M | $-18.15M | $-8.06M | $-16.55M | $-75.50M | $-51.86M | $-38.71M | $-51.48M | $-145.82M | $-474.77M | $-315.39M | $-311.48M | $-283.95M | $-250.11M | $-208.27M | $-220.25M | $-164.42M |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $-145.23M | $-163.62M | $-128.72M | $-57.80M | $-19.93M |
| Depreciation and Amortization | $2.40M | $2.38M | $2.33M | $2.09M | $559.00K |
| Deferred Income Tax | $- | $- | $- | $478.00K | $- |
| Stock Based Compensation | $34.05M | $33.20M | $27.36M | $15.35M | $11.50M |
| Change in Working Capital | $- | $-324.00K | $6.84M | $-7.49M | $-6.77M |
| Accounts Receivables | $- | $- | $-543.00K | $-876.00K | $- |
| Inventory | $- | $- | $- | $- | $- |
| Accounts Payables | $-33.84M | $10.94M | $9.70M | $-4.74M | $-8.88M |
| Other Working Capital | $- | $-11.26M | $-2.32M | $-1.87M | $2.11M |
| Other Non Cash Items | $-26.55M | $7.56M | $18.60M | $1.45M | $487.00K |
| Net Cash Provided by Operating Activities | $-135.34M | $-120.80M | $-73.59M | $-45.92M | $-14.16M |
| Investments in Property Plant and Equipment | $-358.00K | $-807.00K | $-358.00K | $-1.37M | $-569.00K |
| Acquisitions Net | $- | $- | $394.49M | $15.00K | $194.93M |
| Purchases of Investments | $-380.38M | $-303.92M | $-802.50M | $-118.66M | $-194.93M |
| Sales Maturities of Investments | $476.13M | $449.48M | $408.02M | $158.85M | $289.97M |
| Other Investing Activities | $- | $- | $-394.49M | $40.20M | $-194.93M |
| Net Cash Used for Investing Activities | $95.40M | $144.75M | $-394.85M | $38.84M | $94.47M |
| Debt Repayment | $- | $-11.73M | $- | $- | $-1.38M |
| Common Stock Issued | $100.84M | $2.47M | $11.83M | $2.55M | $496.00K |
| Common Stock Repurchased | $-456.00K | $-50.00M | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $26.67M | $-43.00K | $32.19M | $249.75M | $- |
| Net Cash Used Provided by Financing Activities | $127.05M | $-59.30M | $44.02M | $252.30M | $-879.00K |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- |
| Net Change in Cash | $87.11M | $-35.34M | $-424.42M | $245.21M | $79.44M |
| Cash at End of Period | $123.08M | $35.97M | $71.31M | $495.73M | $250.52M |
| Cash at Beginning of Period | $35.97M | $71.31M | $495.73M | $250.52M | $171.08M |
| Operating Cash Flow | $-135.34M | $-120.80M | $-73.59M | $-45.92M | $-14.16M |
| Capital Expenditure | $-358.00K | $-807.00K | $-358.00K | $-1.37M | $-569.00K |
| Free Cash Flow | $-135.69M | $-121.61M | $-73.95M | $-47.29M | $-14.73M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-21.78M | $-32.85M | $-46.66M | $-43.94M | $-42.21M | $-37.31M | $-39.84M | $-44.26M | $-26.41M | $-33.50M | $-32.55M | $-36.26M | $-32.54M | $-6.67M | $-429.00K | $-18.16M | $33.65M | $-23.77M | $-21.55M | $-8.26M |
| Depreciation and Amortization | $601.00K | $596.00K | $595.00K | $605.00K | $604.00K | $592.00K | $587.00K | $593.00K | $606.00K | $585.00K | $571.00K | $573.00K | $385.00K | $669.00K | $911.00K | $125.00K | $144.00K | $138.00K | $137.00K | $140.00K |
| Deferred Income Tax | $- | $- | $- | $- | $-3.15M | $-2.99M | $-2.18M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Stock Based Compensation | $8.18M | $8.19M | $7.54M | $10.13M | $8.11M | $7.81M | $8.43M | $8.86M | $6.68M | $6.27M | $6.66M | $7.74M | $3.98M | $4.36M | $3.69M | $3.31M | $2.98M | $2.81M | $2.74M | $2.98M |
| Change in Working Capital | $-68.78M | $-1.32M | $8.72M | $-7.40M | $-2.66M | $-9.00M | $3.25M | $8.09M | $5.91M | $3.55M | $-4.53M | $1.91M | $1.32M | $-5.46M | $5.29M | $-8.65M | $562.00K | $3.63M | $-1.01M | $-9.96M |
| Accounts Receivables | $-28.57M | $2.16M | $-1.92M | $-238.00K | $-3.58M | $-87.00K | $-1.66M | $-104.00K | $-239.00K | $-147.00K | $-112.00K | $-45.00K | $-115.00K | $-119.00K | $605.00K | $-1.25M | $- | $- | $5.00M | $-5.00M |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $115.00K | $- | $- | $-374.93M | $- | $- | $-367.10M | $-347.57M |
| Accounts Payables | $-40.05M | $3.36M | $8.02M | $-5.17M | $-1.50M | $-2.70M | $6.61M | $8.53M | $4.83M | $1.26M | $75.00K | $3.54M | $-5.32M | $-191.00K | $5.90M | $-5.12M | $-4.45M | $4.06M | $-3.30M | $-5.19M |
| Other Working Capital | $-158.00K | $-6.84M | $2.62M | $-1.99M | $2.42M | $-6.21M | $-1.70M | $-340.00K | $1.32M | $2.44M | $-4.49M | $-1.58M | $6.64M | $-5.15M | $-1.21M | $372.66M | $5.01M | $-424.00K | $364.39M | $347.81M |
| Other Non Cash Items | $15.10M | $15.30M | $18.05M | $13.16M | $4.96M | $4.43M | $4.36M | $2.15M | $2.53M | $5.35M | $5.71M | $5.01M | $1.55M | $85.00K | $126.00K | $167.00K | $248.00K | $178.00K | $69.00K | $-8.00K |
| Net Cash Provided by Operating Activities | $-66.67M | $-10.09M | $-14.38M | $-44.19M | $-34.35M | $-36.47M | $-25.41M | $-24.57M | $-10.69M | $-17.75M | $-24.15M | $-21.01M | $-25.30M | $-7.01M | $9.59M | $-23.20M | $37.58M | $-17.01M | $-19.61M | $-15.11M |
| Investments in Property Plant and Equipment | $-263.00K | $-35.00K | $-33.00K | $-27.00K | $-280.00K | $-162.00K | $-190.00K | $-175.00K | $-175.00K | $-50.00K | $-78.00K | $-55.00K | $-14.00K | $-172.00K | $-863.00K | $-317.00K | $-311.00K | $-88.00K | $-83.00K | $-87.00K |
| Acquisitions Net | $- | $- | $- | $- | $-49.46M | $-30.80M | $20.27M | $-85.57M | $-21.67M | $32.38M | $70.92M | $- | $1.38M | $15.00K | $- | $6.24M | $194.93M | $- | $- | $74.01M |
| Purchases of Investments | $-120.88M | $-51.34M | $-149.15M | $-59.00M | $-66.31M | $-70.05M | $-119.01M | $-48.55M | $-127.58M | $-180.13M | $-172.32M | $-322.48M | $-92.18M | $-16.75M | $-3.50M | $-6.24M | $-38.35M | $-69.62M | $-12.93M | $-74.01M |
| Sales Maturities of Investments | $91.75M | $110.00M | $146.74M | $127.64M | $115.77M | $100.84M | $98.74M | $134.13M | $149.25M | $147.75M | $101.40M | $9.62M | $25.50M | $27.74M | $42.32M | $63.28M | $42.26M | $74.44M | $88.41M | $84.85M |
| Other Investing Activities | $- | $- | $-2.41M | $68.64M | $49.46M | $30.80M | $-20.27M | $85.57M | $21.67M | $-32.38M | $-70.92M | $-312.86M | $-1.38M | $15.00K | $38.82M | $-6.24M | $-194.93M | $4.82M | $75.48M | $-74.01M |
| Net Cash Used for Investing Activities | $-29.40M | $58.62M | $-2.44M | $68.62M | $49.18M | $30.64M | $-20.45M | $85.40M | $21.50M | $-32.43M | $-71.00M | $-312.91M | $-66.69M | $10.84M | $37.96M | $56.73M | $3.60M | $4.73M | $75.39M | $10.75M |
| Debt Repayment | $- | $-26.90M | $33.97M | $- | $- | $- | $-1.80M | $-1.27M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-1.38M |
| Common Stock Issued | $555.00K | $98.50M | $979.00K | $811.00K | $264.00K | $160.00K | $783.00K | $1.26M | $3.42M | $2.70M | $865.00K | $4.84M | $2.39M | $241.00K | $554.00K | $167.00K | $126.00K | $370.00K | $- | $- |
| Common Stock Repurchased | $-456.00K | $- | $- | $- | $- | $- | $-12.47M | $-37.53M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $27.47M | $-370.00K | $- | $-14.44M | $-5.42M | $-3.23M | $- | $-43.00K | $-1.47M | $34.33M | $-433.00K | $-235.00K | $251.34M | $- | $- | $- | $126.00K | $263.00K | $71.00K | $36.00K |
| Net Cash Used Provided by Financing Activities | $27.57M | $71.23M | $34.95M | $-6.69M | $-5.16M | $-3.07M | $-13.49M | $-37.57M | $1.95M | $37.03M | $432.00K | $4.61M | $251.34M | $241.00K | $554.00K | $167.00K | $126.00K | $263.00K | $71.00K | $-1.34M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Change in Cash | $-68.50M | $119.76M | $18.13M | $17.73M | $9.67M | $-8.91M | $-59.36M | $23.25M | $12.76M | $-13.15M | $-94.71M | $-329.32M | $159.34M | $4.07M | $48.11M | $33.69M | $41.30M | $-12.02M | $55.85M | $-5.70M |
| Cash at End of Period | $123.08M | $191.58M | $71.82M | $53.70M | $35.97M | $26.30M | $35.21M | $94.56M | $71.31M | $58.55M | $71.70M | $166.41M | $495.73M | $336.39M | $332.31M | $284.21M | $250.52M | $209.21M | $221.23M | $165.38M |
| Cash at Beginning of Period | $191.58M | $71.82M | $53.70M | $35.97M | $26.30M | $35.21M | $94.56M | $71.31M | $58.55M | $71.70M | $166.41M | $495.73M | $336.39M | $332.31M | $284.21M | $250.52M | $209.21M | $221.23M | $165.38M | $171.08M |
| Operating Cash Flow | $-66.67M | $-10.09M | $-14.38M | $-44.19M | $-34.35M | $-36.47M | $-25.41M | $-24.57M | $-10.69M | $-17.75M | $-24.15M | $-21.01M | $-25.30M | $-7.01M | $9.59M | $-23.20M | $37.58M | $-17.01M | $-19.61M | $-15.11M |
| Capital Expenditure | $-263.00K | $-35.00K | $-33.00K | $-27.00K | $-280.00K | $-162.00K | $-190.00K | $-175.00K | $-175.00K | $-50.00K | $-78.00K | $-55.00K | $-14.00K | $-172.00K | $-863.00K | $-317.00K | $-311.00K | $-88.00K | $-83.00K | $-87.00K |
| Free Cash Flow | $-66.94M | $-10.12M | $-14.41M | $-44.22M | $-34.63M | $-36.64M | $-25.60M | $-24.74M | $-10.86M | $-17.80M | $-24.23M | $-21.07M | $-25.32M | $-7.18M | $8.73M | $-23.52M | $37.27M | $-17.10M | $-19.69M | $-15.20M |
AnaptysBio Dividends
Explore AnaptysBio's dividend history, including dividend yield, payout ratio, and historical payments.
AnaptysBio News
Read the latest news about AnaptysBio, including recent articles, headlines, and updates.
Anaptys Announces Stock Repurchase Plan
SAN DIEGO, March 24, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that its Board of Directors has authorized a Stock Repurchase Plan under which the Company may repurchase up to $75,000,000 of the Company's outstanding common stock, par value $0.001 per share.
Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Announced rosnilimab, a PD-1 depleter and agonist, achieved positive results from Phase 2b rheumatoid arthritis (RA) trial and highest-ever reported CDAI LDA response over 6 months Full clinical and translational data for rosnilimab in RA in Q2 2025 Top-line Phase 2 data for rosnilimab in ulcerative colitis (UC), moved up to Q4 2025 Phase 1a trial in healthy volunteers ongoing for ANB033, our CD122 antagonist, and Phase 1a trial to initiate this quarter for ANB101, our BDCA2 modulator Announced exclusive global license agreement with Vanda Pharmaceuticals to develop and commercialize imsidolimab, an IL-36R antagonist Year-end 2024 cash and investments of ~$420 million and reiterating cash runway through year-end 2027 SAN DIEGO, Feb. 27, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported financial results for the fourth quarter and year ended December 31, 2024, and provided a business update. “Rosnilimab's positive Phase 2b data in rheumatoid arthritis has revealed impressive safety, tolerability and three-month efficacy data that was sustained and surpasses six-month data from competitor all-active, head-to-head trials.
Anaptys Announces Participation in March Investor Conferences
SAN DIEGO, Feb. 27, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its executive leadership team, are scheduled to participate in multiple upcoming investor conferences: TD Cowen 45 th Annual Healthcare Conference, Boston, MA Format – Fireside chat and one-on-one investor meetings Date and Time – Tuesday, Mar. 4, 2025 at 1:10pm ET / 10:10am PT Leerink Partners 2025 Global Healthcare Conference, Miami, FL Format – Fireside chat and one-on-one investor meetings Date and Time – Tuesday, Mar. 11, 2025 at 10:40am ET / 7:40am PT Barclays 27 th Annual Global Healthcare Conference, Miami, FL Format – Presentation and one-on-one investor meetings Date and Time – Wednesday, Mar. 12, 2025 at 8:30am ET / 5:30am PT Live webcasts of the fireside chats and presentation will be available on the investor section of the Anaptys website at http://ir.anaptysbio.com/events. Replays of the webcasts will be available for at least 30 days following the events.
Anaptys Announces Rosnilimab Achieved Positive Results in RA Phase 2b Trial and Highest Ever Reported CDAI LDA Response Over 6 Months
Achieved statistical significance on primary endpoint at Week 12 on mean change from baseline DAS-28 CRP across all rosnilimab doses vs. placebo Achieved statistical significance on key secondary endpoints at Week 12 on ACR20, ACR50 and CDAI LDA Demonstrated highest ever reported responses on key secondary endpoints at Week 14 on ACR20, ACR50, ACR70 and CDAI LDA 69% of rosnilimab-treated patients achieved CDAI LDA at Week 14 and appear to show sustained CDAI LDA and ACR50 responses and potentially deepening ACR70 responses out to Week 28 Robust pharmacological activity observed in reduction of PD-1high T cells, increase in total Tregs and reduction of CRP across all doses Rosnilimab was safe and well tolerated with similar adverse event rates vs.
Anaptys to Announce Top-line Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, in Rheumatoid Arthritis on Feb. 12, 2025
SAN DIEGO, Feb. 11, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, will host an investor call and live webcast to review top-line data from the global Phase 2b RENOIR clinical trial of investigational rosnilimab, a depleter and agonist of PD-1+ T cells, for moderate-to-severe rheumatoid arthritis on Wednesday, Feb. 12, 2025, at 8:30am ET / 5:30am PT.
Anaptys to Present at the Guggenheim SMID Cap Biotech Conference
SAN DIEGO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, will present at the Guggenheim SMID Cap Biotech Conference on Wednesday, Feb. 5, 2025 at 1:00pm ET / 10:00am PT.
Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist
Imsidolimab has successfully completed two global Phase 3 studies in Generalized Pustular Psoriasis Vanda expects to immediately begin preparing BLA and MAA applications for the US and EU Anaptys to receive $15 million from Vanda, comprised of a $10 million upfront payment and $5 million for existing drug supply Anaptys to receive a 10% royalty on global net sales of imsidolimab WASHINGTON and SAN DIEGO , Feb. 3, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) and AnaptysBio, Inc. (Anaptys) (Nasdaq: ANAB) today announced an exclusive, global license agreement for the development and commercialization of imsidolimab (IL-36R antagonist mAb), which has successfully completed two registration-enabling global Phase 3 trials, GEMINI-1 and GEMINI-2, evaluating the safety and efficacy of imsidolimab in patients with Generalized Pustular Psoriasis (GPP). GPP is a rare skin disorder often caused by mutations in the IL36RN gene that codes for a regulatory protein that balances the activity of the proinflammatory IL-36 family of cytokines.
Anaptys to Present at the 43rd Annual J.P. Morgan Healthcare Conference
SAN DIEGO, Jan. 07, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 14, 2025 at 4:30pm PT / 7:30pm ET.
AnaptysBio Discontinues Investment In Eczema Candidate After Disappointing Data
On Wednesday, AnaptysBio, Inc. ANAB announced that investigational ANB032, a BTLA agonist, did not meet the primary and secondary endpoints in any of the doses studied in the ARISE-AD trial as a monotherapy for moderate-to-severe atopic dermatitis (AD) or eczema.
Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis
SAN DIEGO, Dec. 11, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that investigational ANB032, a BTLA agonist, did not meet the primary and secondary endpoints in any of the doses studied in the global, 201-patient ARISE-AD trial as a monotherapy for moderate-to-severe atopic dermatitis (AD) or eczema. ANB032 was well tolerated with no safety signals observed.
Down -32.84% in 4 Weeks, Here's Why You Should You Buy the Dip in AnaptysBio (ANAB)
The heavy selling pressure might have exhausted for AnaptysBio (ANAB) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Anaptys Announces Participation in November and December Investor Conferences
SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its senior management team, are scheduled to participate in multiple upcoming investor conferences:
Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update
SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported financial results for the third quarter ended Sept. 30, 2024 and provided a business update.
Anaptys Announces Participation in September Investor Conferences
SAN DIEGO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its senior management team, are scheduled to participate in multiple upcoming investor conferences:
AnaptysBio: Top-Line AD Data End Of 2024 Could Be Turning Point
AnaptysBio, Inc. 14-week results from the phase 2b study, using ANB032 for the treatment of patients with moderate-to-severe Atopic Dermatitis, expected in December 2024. The global Atopic dermatitis market is expected to reach $19.49 billion by 2034. Top-line 12-week data from the phase 2b study, using rosnilimab for the treatment of patients with moderate-to-severe rheumatoid arthritis, expected in Q1 of 2025.
Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering
Led by long-standing investor EcoR1 Capital with participation from additional existing and new investors, including Sanofi Led by long-standing investor EcoR1 Capital with participation from additional existing and new investors, including Sanofi
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for ANAB.